Objective: The term “triple negative” has traditionally been used to characterize a subtype of breast cancer that lacks estrogen, progesterone, and Her2 receptor expression. Triple negative breast cancers behave aggressively, are associated with poor prognosis, and have limited treatment options. It is unknown whether similar phenotypes found in other cancer types, such as endometrial cancer, harbor similar molecular alterations and prognosis. We sought to
compare genetic and molecular features of triple negative endometrial cancers (TNEC) with non-TNEC to identify possible therapeutic targets.